• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Augmedix Awarded on Newsweek's World's Best Digital Health Companies 2024 List

    4/25/24 4:05:00 PM ET
    $AUGX
    Business Services
    Consumer Discretionary
    Get the next $AUGX alert in real time by email

    SAN FRANCISCO, April 25, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, has been named on Newsweek's list of The World's Best Digital Health Companies 2024. This prestigious award was presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awardees was unveiled on April 24th, 2024, and is available on the Newsweek website.

    Augmedix's inclusion highlights its commitment to empowering clinicians by relieving them of administrative burdens through ambient AI, data management, and trust. Its platform seamlessly converts natural conversations into organized medical notes, structured data, and real-time point-of-care notifications, enhancing efficiency and clinical decision-making.

    The World's Best Digital Health Companies 2024 ranking lists the top 400 companies from over 35 different countries. The winners were ranked across seven market segments: Data Analytics, Diagnostics, Health Records, Medical Management, Prevention, Telehealth and Treatment. The top list is based on three pillars:

    • Financial Performance: Statista analyzed historical financial data from publicly available sources such as annual reports, company websites, media outlets, and databases. Companies also had the opportunity to submit data using an online application form, accessible via Newsweek.com.
    • Impact: Statista cooperated with data and market intelligence company HolonIQ to assess a company in different impact dimensions, encompassing factors such as the quality and uniqueness of their product/service, as well as the expertise of their leadership team.
    • Online Engagement: Statista analyzed traffic data from company websites and apps to assess the engagement of users with their product/service.

    Based on the results of the study, Augmedix is proud to be recognized on Newsweek's World's Best Digital Health Companies 2024 list.

    Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, relevant business data, and various market and consumer studies and surveys.

    "Being recognized by Newsweek as one of the World's Best Digital Health Companies in 2024 is an honor for Augmedix. It speaks to the dedication and ingenuity of our team, who continuously push the boundaries to innovate and improve healthcare technology," said Manny Krakaris, CEO of Augmedix. "This recognition strengthens our commitment to lead the industry forward, leveraging cutting-edge technology to support healthcare providers and transform healthcare as we know it. Our dedication to our clients remains unwavering, as evidenced by our newest product, Augmedix Go, a fully automated AI solution designed to meet the growing need for high-quality medical documentation, which has now successfully rolled out to emergency departments and over 50 specialties in acute and ambulatory care settings. We're proud to offer solutions that not only streamline administrative tasks but also empower healthcare providers to focus more on patient care."

    About Augmedix

    Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.

    The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decision support.

    Incorporating data from millions of interactions across all care settings, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes.

    Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" that involve a number of risks and uncertainties. Words such as "believes," "may," "will," "estimates," "potential," "continues," "anticipates," "intends," "expects," "could," "would," "projects," "plans," "targets," "excited," "optimistic," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding Augmedix being committed to empowering clinicians by relieving them of administrative burdens through ambient AI, data management, and trust; enhancing efficiency and clinical decision-making by seamlessly converting natural conversations into organized medical notes, structured data, and real-time point-of-care notifications; Augmedix's ability to innovate and improve healthcare technology; Augmedix's commitment to lead the industry forward, leveraging cutting-edge technology to support healthcare providers and transform healthcare as we know it; Augmedix's unwavering dedication to its clients; and Augmedix Go streamlining administrative tasks and allowing healthcare providers to focus more on patient care. Actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the U.S. Securities and Exchange Commission on March 26, 2024, as well as other documents that may be filed by us from time to time with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Contact Information

    Investors:

    Matt Chesler, CFA

    FNK IR

    646-809-2183

    [email protected]

    [email protected]

    Media:

    Kaila Grafeman

    Augmedix

    [email protected]



    Primary Logo

    Get the next $AUGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUGX

    DatePrice TargetRatingAnalyst
    7/22/2024Buy → Hold
    Lake Street
    7/22/2024$3.00 → $2.35Buy → Neutral
    B. Riley Securities
    5/14/2024$5.00Buy → Hold
    Maxim Group
    5/14/2024$5.00 → $1.50Outperform → In-line
    Evercore ISI
    4/3/2024$5.50Buy
    B. Riley Securities
    12/15/2023$6.00In-line
    Evercore ISI
    3/7/2022$6.00Buy
    Lake Street
    1/21/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $AUGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Commure Completes Merger with Augmedix

    SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

    10/2/24 8:23:42 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

    SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu

    8/12/24 4:01:00 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

    SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

    8/6/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    SEC Filings

    View All

    SEC Form 15-12G filed by Augmedix Inc.

    15-12G - Augmedix, Inc. (0001769804) (Filer)

    10/15/24 9:32:28 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    SEC Form EFFECT filed by Augmedix Inc.

    EFFECT - Augmedix, Inc. (0001769804) (Filer)

    10/4/24 12:15:04 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    SEC Form EFFECT filed by Augmedix Inc.

    EFFECT - Augmedix, Inc. (0001769804) (Filer)

    10/4/24 12:15:02 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Redmile Group, Llc returned $75,402,504 worth of shares to the company (32,086,172 units at $2.35) (SEC Form 4)

    4 - Augmedix, Inc. (0001769804) (Issuer)

    10/4/24 5:01:03 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    SEC Form 4 filed by Director Faulkner Robert C.

    4 - Augmedix, Inc. (0001769804) (Issuer)

    10/4/24 5:00:14 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Director Febbo William J returned $382,070 worth of shares to the company (162,583 units at $2.35), closing all direct ownership in the company (SEC Form 4)

    4 - Augmedix, Inc. (0001769804) (Issuer)

    10/4/24 1:17:00 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Augmedix downgraded by Lake Street

    Lake Street downgraded Augmedix from Buy to Hold

    7/22/24 8:25:03 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously

    7/22/24 8:02:58 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix downgraded by Maxim Group with a new price target

    Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00

    5/14/24 8:17:17 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ginocchio Paul bought $48,500 worth of shares (10,000 units at $4.85), increasing direct ownership by 8% to 128,000 units (SEC Form 4)

    4 - Augmedix, Inc. (0001769804) (Issuer)

    11/27/23 7:00:06 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Redmile Group, Llc bought $6,000,000 worth of shares (1,500,000 units at $4.00) (SEC Form 4)

    4 - Augmedix, Inc. (0001769804) (Issuer)

    11/22/23 4:15:24 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Leadership Updates

    Live Leadership Updates

    View All

    Augmedix to Join Forces with Commure

    SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price

    7/19/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

    SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog

    5/29/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

    SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr

    4/4/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

    SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

    10/4/24 5:00:14 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Augmedix Inc.

    SC 13G - Augmedix, Inc. (0001769804) (Subject)

    7/29/24 5:23:20 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

    SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

    7/19/24 7:45:47 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Financials

    Live finance-specific insights

    View All

    Commure Completes Merger with Augmedix

    SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

    10/2/24 8:23:42 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

    SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

    8/6/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

    SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a

    5/13/24 4:03:00 PM ET
    $AUGX
    Business Services
    Consumer Discretionary